An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2015
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Trebananib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
- 22 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 30 Nov 2013 New trial record